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Abstract  
Purpose: Oral contraceptive (OC) use reduces peak aerobic capacity     2peak), however, 
whether it also influences adaptations to training has yet to be determined. This study aimed to 
examine the influence of OC use on peak performance [peak power output (PPO)] and 
physiological adaptations [   2peak and peak cardiac output    peak)] following sprint interval 
training (SIT) in recreationally-active women. 
Methods: Women taking an OC (n=25) or experiencing natural regular menstrual cycles (MC; 
n=16                                                      2peak             peak before, 
immediately after, and four weeks following 12 sessions of SIT. The SIT consisted of 10, one-
minute efforts at 100-120% PPO in a 1:2 work:rest ratio. 
Results: Though    2peak increased in both groups following SIT (both p<0.001), the MC group 
showed greater improvement (OC +8.5%; MC +13.0%; p=0.010). Similarly,   peak increased in 
both groups, with greater improvement in the MC group (OC +4.0%; MC +16.1%; p=0.013). 
PPO increased in both groups (OC +13.1%; MC +13.8%; NS). All parameters decreased four 
weeks after SIT cessation, but remained elevated from pre-training levels; the OC group showed 
more sustained training effects in    2peak (OC -4.0%; MC -7.7%; p=0.010). 
Conclusion: SIT                                                   -                       
                   2peak       peak adaptation. A follow-up period indicated that              
          2peak adaptations, suggesting that OC use may influence the time course of 
physiological training adaptations. Therefore, OC use should be verified, controlled for, and 
considered when interpreting physiological adaptations to exercise training in women. Key 
words: aerobic capacity; athletic performance; cardiac output; detraining; female; ovarian 
hormones  
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Introduction  
Exogenous hormones introduced through oral contraceptive (OC) use may influence endurance 
exercise performance by reducing maximal exercise capacity (8, 24, 27), increasing fat-mass (5) 
and changing the metabolic (23), thermoregulatory (36), cardiovascular (12) and ventilatory (9) 
responses to exercise. While OC use has been shown                                    
    2max) in both highly trained (24) and recreationally active (8, 27) women, whether 
physiological, cardiovascular and performance adaptations to endurance exercise training are 
influenced by OC use remains unclear.  
 
Near-maximal to maximal interval training, classified as either high-intensity interval training 
(80-100% peak heart rate) or sprint interval training (SIT) (target at or above 100% maximal 
aerobic capacity) (42) has been extensively studied in both trained and untrained men, with 
results showing rapid improvements in peak aerobic capacity (   2peak) and endurance 
performance in as little as two weeks (1, 7, 18). Relatively few studies have investigated 
adaptations to SIT in women (1, 14, 15, 39, 41). Of these, only one (41) controlled for menstrual 
cycle phase, by measuring    2peak in the follicular phase (determined by onset of menstruation), 
yet did not verify serum ovarian hormone concentrations and excluded OC users. Elevated 
oestradiol and progestin levels in OCs attenuate submaximal cardiovascular responses to 
exercise (25), potentially by altering fluid retention mechanisms and blood volume changes (37), 
and may therefore alter the responses to exercise training in recreationally active women. 
Whether elevated exogenous oestradiol and progestin levels in OCs may alter responses to 
exercise training and maintenance of adaptations following training in recreationally-active 
women remains to be determined. 
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To date, only one study has investigated maintenance of training adaptations following SIT in 
women (31). Two weeks following completion of SIT,                                            
   2max                                           2max improvements retained. OC use, 
menstrual status and/or menstrual cycle phase were not considered/reported.  
 
Therefore, the primary aim of this study was to assess the influence of OC use, compared to 
natural menstruation, on peak physiological, cardiovascular and performance adaptations to SIT 
in recreationally-active women while stringently verifying ovarian hormone concentrations. The 
secondary aim was to investigate the influence of OC use, compared to natural menstruation, on 
the sustainability of gained adaptations following a four-week follow-up. 
 
Methods  
Overview  
Following a baseline assessment of serum hormone levels and    2peak, peak power output 
(PPO), peak cardiac output    peak), peak stroke volume (SVpeak), peak heart rate (HRpeak), peak 
rating of perceived exertion (RPEpeak                                                          
        2slope), participants with either natural menstrual cycles (no current hormone 
contraception) or using an OC completed a four-week SIT program with reassessment of all 
measures following completion of the training program and after a four-week follow-up period. 
 
Participants  
Healthy, recreationally-active (regularly completing at least 150 minutes of self-reported 
moderate to vigorous physical activity per week, but not currently training for, or competing at 
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state or national level sport competition) women, who were either long-term (minimum six 
months uninterrupted) monophasic combined OC users (n=25) or experiencing regular natural 
menstrual cycles (MC; n=22) participated in the study. All experimental procedures were 
approved by the Human Research Ethics Committee of The University of Queensland, ethical 
clearance #2012001438, and all participants provided written informed consent.  
 
Nutrition, hydration and exercise control measures 
Prior to all experimental trials, participants were required to: (a) complete a 24 h food diary and 
consume, as closely as possible, the same types and quantities of food and beverages the day 
before testing;                     ≥8 h); (c) consume a standardised moderate carbohydrate (1.5 
 ∙  -1 body mass carbohydrate) pre-trial meal 1 h prior to arrival at the laboratory for testing; (d) 
abstain from caffeine, alcohol and other stimulants and depressants for 24 h, as well as record 
any additional medications or supplements; and (e) maintain a euhydrated state, avoid hot, humid 
conditions and record the volume of water consumed.  
 
Participants were encouraged to maintain their normal physical activity levels throughout the 
study; however, were asked to refrain from strenuous physical activity for 24 h prior to each trial 
to ensure maximal effort. A physical activity questionnaire was completed prior to each exercise 
                                       ’                                                             
On the days of testing, participants were requested to arrive at the laboratory in a rested state. A 
pre-trial preparation checklist was completed and signed by participants upon arrival at the 
laboratory to confirm compliance to pre-testing requirements. 
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Hormone verification and testing  
All MC participants completed a menstrual cycle diary adapted from Prior, Vigna and Alojada 
(30) for three consecutive cycles to determine average cycle length, calculated as the number of 
days between the onset of consecutive menses. The menstrual diary determined approximate 
days of follicular and luteal phases, and ovulation (28). Participants taking an OC mapped their 
cycle based on their pill packaging, with day one of the cycle coinciding with the first inactive 
(sugar) pill of the package; if a participant reported missing two or more consecutive pills in one 
cycle, testing was delayed by one cycle until adherence was confirmed. 
 
Urinary ovulation prediction testing was performed during the experimental cycle to verify cycle 
phase and ovulatory status in the MC group and confirm cycle control by exogenous hormones 
in the OC group. Participants were provided a home urine ovulation prediction testing kit 
(Discover
®
 7-Day Pregnancy Planning kit, Church and Dwight Australia Pty Ltd.) and instructed 
                          ’  directions to perform ovulation prediction testing for seven 
consecutive days during one cycle. Participants visually inspected the test strip and the result was 
confirmed by the lead researcher via photographic record. Two days following the urinary 
luteinising hormone surge, ovulation was assumed to have occurred, with the mid-luteal phase 
beginning approximately six to eight days following ovulation. An absence of the luteinising 
hormone surge during the menstrual cycle (non-OC use) indicated absence of ovulation. In this 
case, testing was delayed (n=3) by a further cycle until a positive ovulation prediction test was 
recorded. If three consecutive non-ovulatory cycles (n=0) were experienced by participants in the 
MC group, participants were excluded from the study.  
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MC participants performed testing during the estimated mid-luteal phase, six to eight days 
following a positive ovulation prediction test ovulation (29). OC participants performed testing 
in the final two weeks of the active pill phase (days 15 to 28). On the day of the trial, venous 
blood (12 mL) was sampled from an antecubital vein for later measurement of serum hormone 
concentrations. These methods are described in more detail in Schaumberget al. (34). 
 
Body composition  
Height and body mass were measured using a stadiometer (Seca, Birmingham, UK) and 
electronic scales (A&D Mercury, Pty Ltd., Thebarton, AUS), respectively. Body composition 
was assessed by dual-energy x-ray absorptiometry (Hologic Discovery W, QDR 4500A, 
Waltham, Mass., USA). Scans were analysed using software (APEX version 3.3) provided by the 
manufacturer (Hologic, Bedford, Va., USA) and according to the manufacturer’  instructions. 
The coefficients of variation (CV) in our laboratory for whole body mass, lean body mass, fat 
mass and body fat percentage are 0.1%, 0.4%, 1.2% and 1.2%, respectively.  
 
Measurement of peak aerobic capacity and peak power output  
A    2peak familiarisation session was completed prior to the first experimental trial to minimise 
any learning effects and ensure participant familiarity with the protocol.        2peak protocol 
involved participants performing a five-minute self-selected warm up prior to a continuous 
              5 W∙   -1) exercise test on an electronically-braked cycle ergometer (L    
                                          2peak, ventilatory threshold,             2slope and 
PPO. Before each test, the O2 and CO2 analysers were calibrated as recommended by the 
manufacturer. Participants continued until volitional fatigue, whereby the required cadence could 
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not be maintained despite strong verbal encouragement. Heart rate and rate of perceived exertion 
(6) were recorded each minute and respiratory gas exchange was continuously recorded via 
automated indirect calorimetry (Parvo Medics' TrueOne® 2400 Indirect Calorimetry System, 
Utah, USA) for calculation of ventilatory parameters. For the incremental test, data was averaged 
in 15-second epochs.    2peak                               2 value attained during a 15-second 
period (33, 38). 
 
Measurement of cardiovascular parameters  
During exercise, heart rate (HR), stroke volume (SV) and cardiac output    ) were measured 
continuously using impedance cardiology (PhysioFlow
®
, Manatec Biomedical, France) (10, 32); 
this method has been described elsewhere (10). Two sets of electrodes (Skintact FS-50, 
Leonhard Lang Gmbh, Austria) - one transmitting, one sensing - were applied above the supra-
clavicular fossa at the left base of the neck, and along the xiphoid process. Another two 
electrodes were used to monitor a single electrocardiographic signal (ECG; CM5 position). 
Blood pressure was assessed (Digital blood pressure monitor, UA-767, A&D Instruments Ltd., 
UK) as part of standard calibration process for the PhysioFlow
®
 prior to the incremental exercise 
test. HR, SV, and    data were sampled at 15-second intervals (38). The coefficient of variation 
for SV and    during repeated cycle ergometer    2peak tests in healthy, fit men, assessed using 
the PhysioFlow
®
 has been reported as 3.6 and 3.4%, respectively (22).  
 
Sprint interval training protocol  
Participants completed three supervised SIT sessions per week for four weeks, with a minimum 
of 36 h between sessions. Following a five-minute standardised warm-up at an intensity of 50 W 
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and a self-selected revolutions per minute (RPM), participants completed the SIT protocol 
comprising one minute of work followed by two minutes of passive recovery in a 1:2 work:rest 
ratio (19, 31). The work interval intensity was self-selected at the maximal sustainable effort 
between 100-120% of PPO determined in the baseline peak exercise test. Participants completed 
10 one-minute repetitions, totalling 10 minutes of work per session, with a total time 
commitment of 40 minutes per session. Peak heart rate, , RPE, average power output and PPO 
were recorded for each interval and used to calculate protocol compliance. All exercise sessions 
were completed on an air- and magnetically-braked cycle ergometer (Wattbike Ltd, Nottingham, 
England). Following completion of each SIT session participants completed a five-minute active 
cool-down on the cycle ergometer at a self-selected intensity.  
 
Follow-up period 
Following completion of the four-week SIT program, participants were instructed to return to the 
physical activity levels they were undertaking previous to the SIT protocol. Physical activity was 
monitored via a questionnaire (Active Australia Survey, Australian Institute of Health and 
Welfare, 2003) following the duration of the follow-up period. Participants completed testing 
procedures identical to baseline four weeks following completion of the SIT training program. 
Participants were excluded from the follow-up assessment if they commenced or ceased an OC 
in the preceding month or fell pregnant.  
 
Blood sampling, storage and analysis  
Venous blood was collected into prepared vacuum tubes containing K3EDTA or micronised 
silica until centrifugation. The serum tubes (micronised silica) were allowed to clot at room 
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temperature, and the plasma tubes (K3EDTA) were stored on ice. After 30 min, samples were 
centrifuged at 1100 x G for 10 min at 4° C. Serum and plasma was removed, placed into separate 
0.4 mL aliquots and stored at -80° C until later analysis. Plasma samples were analysed for 
oestradiol, progesterone and testosterone, whilst serum samples were analysed for sex-hormone 
binding globulin (SHBG) using a Cobas e411 electrochemilumescence immunoassay 
autoanalyser (Roche Diagnostics, Germany) and manufacturer-recommended Elecsys assays. 
Manufacturer-supplied reagents were used, and instruments calibrated according to the 
            ’                The CVs in our laboratory for oestradiol-II, progesterone, 
testosterone and SHBG are 3.1%, 5.1%, 4.8% and 3.1%, respectively. 
 
Statistical analysis 
A sample size calculation indicated that to detect a 3.5  L∙  -1∙min-1              2peak (1 MET) 
with a SD of 3.5  L∙  -1∙min-1, alpha=0.05 and power=80% (ES=1), and 30% participant 
withdrawal prior to post-testing, a total of 44 participants would be required (22 participants per 
group) (Power and Sample Size Software, Vanderbilt University, TN). As session attendance 
was 100%, data were analysed per-protocol using Microsoft Excel
®
 2007 and SPSS
®
 (version 
22.0, SPSS, Inc., Chicago, IL). Normality of distribution was tested using the Kolmogorov-
Smirnov test; when not normally distributed, data were log-transformed and re-checked for 
normality of distribution. A                                                         ’      
        ’                                    -test, mixed-model one-way and two-way repeated 
measures analysis of variance (ANOVA) (with a main effect for training x group). To locate the 
source of significant differences, the Bonferroni post-hoc test was used. Homogeneity of 
                             M      ’                      W                                 
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was violated (p<0.05), the F-statistic was adjusted using the Greenhouse-Geisser correction. 
W     M      ’                                                          -hoc analyses assumed 
sphericity (40).Magnitude-based inferences (4, 21) calculated the between-trial standardised 
differences or effect sizes [ES, 95% confidence interval (CI)] using the pooled standard deviation 
(11) and standard threshold values (3). All tests were two-tailed and statistical significance was 
set at p<0.05. Parametric results are given as the mean, standard deviation and 95% confidence 
interval (CI), [mean±SD (95% CI)]; non-parametric results are given as the median and 
interquartile range and 95% CI, [median (IQR) (95% CI)] unless stated otherwise.  
 
Results 
Participants 
Participant recruitment and retention is displayed in Figure 1. Six of the 22 participants recruited 
to the MC group were excluded from analysis on the basis of potential luteal phase deficiency 
(LPD), i.e. they did not satisfy the mid-luteal serum progesterone criterion of >6 ng.mL
-1
 on the 
day of testing. These participants completed the intervention and a sub-analysis of the data are 
presented in the supplemental content (see Table, Supplemental Digital Content, Luteal phase 
deficient participant demographics, control parameters, body composition, serum hormone 
concentrations and peak exercise parameters at baseline, following training and after a four-week 
follow-up period, http://links.lww.com/MSS/A819). Therefore, 16 participants who met the 
progesterone criterion and therefore exhibited normal menstrual function were included in the 
MC group for analysis. All 25 participants recruited to the OC group were taking a monophasic 
combined oestradiol and progestin formulation, with a low ethinyl oestradiol (20-30 μ         
second or third generation progestin. There were variations in androgenic (n=5), anti-androgenic 
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(n=5) and non-androgenic (n=15) formulations (calculated using the method of Greer et al. (20)) 
subsequent analyses confirmed androgenicity of OC type (indicative of progestin type and 
oestradiol ratio) did not influence baseline characteristics or outcome measures.  
 
There were no differences in participant demographics at baseline between groups (p=0.574-
0.988; Table 1). Physical activity, energy intake and body composition parameters were not 
different within or between groups, at any time point. At baseline, the MC group had 
significantly higher oestradiol, progestogen and free androgen index (all p<0.001), and 
significantly lower sex-hormone-binding globulin (p<0.001) concentrations compared to the OC 
group. There was no difference between groups for total testosterone (p=0.192). Of the 
participants identified as LPD, it is interesting to note that these participants were younger, had 
longer menstrual cycles, lower body mass and body fat indices, and higher free androgen index 
than both the OC and MC groups (see Table, Supplemental Digital Content, Luteal phase 
deficient participant demographics, control parameters, body composition, serum hormone 
concentrations and peak exercise parameters at baseline, following training and after a four-week 
follow-up period, http://links.lww.com/MSS/A819). 
 
Adherence to protocol 
Of the 25 OC participants and 16 MC participants who undertook the training protocol, all 
participants completed all 12 training sessions and all 120 intervals (i.e. 100% attendance). There 
were three minor adverse events (one participant fainted during a training session, and one 
participant had two separate asthma incidents requiring basic first aid). Target power output was 
achieved in 79.0% of intervals in the OC group and 73.3% of intervals in the MC group; there 
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was no difference between groups. There were also no between-group differences in mean rating 
of perceived exertion, heart rate, or power output; results and p-values are presented in Table 2. 
 
Peak aerobic capacity  
There was no significant difference between the MC and OC               2peak at baseline 
[t(39)=-0.278;p=0.783]                         2peak increased from baseline in both groups [OC; 
t(24)=-5.108; p<0.001, MC; t(15)=-11.760; p<0.001] and remained significantly increased from 
baseline at follow-up in both groups [OC; t(22)=-3.840; p=0.001, MC; t(12)=-5.049; p<0.001]; 
data are presented in Table 2. The MC                                        2peak following 
training compared to the OC group [OC +8.5% vs. MC +13.0%; F(1,45)=7.322; p=0.010], but 
also a greater decline at follow-up [OC -4.0% vs. MC -7.7%; F(1,40)=6.610; p=0.014]. 
Standardised between-group differences for within-                    ’  D , presented in 
Figure 2, demonstrated that the OC                             2peak adaptation to training [-
0.22±0.18 (-0.40- -0.04); 0/40/60% higher/trivial/lower than MC]. W       2peak was adjusted 
for body mass and lean body mass, the above significant relationships remained true. 
 
Peak power output 
There was no between-group difference for PPO at baseline [t(39)=-0.127; p=0.899], post-
training [t(39)=-0.283; p=0.779] or follow-up [t(35)=-0.053; p=0.958]. PPO increased following 
training in both groups [OC; t(24)=-15.371; p<0.001, MC; t(15)=-9.249; p<0.001]. At follow-up, 
PPO decreased from post-training in both groups [OC; t(22)=5.061; p<0.001, MC; t(13)=3.085; 
p=0.009], but remained above baseline [OC; t(22)=-9.148; p<0.001, MC; t(13)=-5.737; p<0.001] 
. There was no difference between groups [F(1.776,72.820)=0.048; p=0.938] at any time point; 
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data are presented in Table 2. Standardised between-group differences for within-group changes 
      ’  D , presented in Figure 2, demonstrated a trivial between-group difference in PPO 
adaptation to training [-0.04±0.19 (-0.24-0.15); 1/94/5% higher/trivial/lower than MC].  
 
Peak cardiac output  
There was no significant between-group difference in peak cardiac output (  peak) at baseline 
(p=0.385) or follow-up (p=0.804), but the MC                             peak following 
training (p=0.002).                       peak increased in both the OC [t(24)=-3.348; p=0.003] 
and MC [t(15)=-6.742; p<0.001] groups, and returned to pre-training values at follow-up (OC; 
t(22)=-0.986; p=0.335, MC; t(13)=-1.735;p=0.107]. There was a significant group x time 
interaction for the OC group compared to the MC group following training [OC group +4.0% vs. 
MC group +16.1%; F(1,39)=6.711, p=0.013]; data are presented in Table 2. There was also a 
significant group x time interaction for the MC groups vs. the LPD sub-group following training 
[MC group +16.1% vs. LPD sub-group +6.3%; F(1,20)=5.328, p=0.032]; data are presented in 
the supplemental content (see Table, Supplemental Digital Content, Luteal phase deficient 
participant demographics, control parameters, body composition, serum hormone concentrations 
and peak exercise parameters at baseline, following training and after a four-week follow-up 
period, http://links.lww.com/MSS/A819). Standardised between-group differences for within-
                    ’  D                           group                      peak adaptation 
to training [-0.51±0.39 (-0.90- -0.12); 0/6/94% higher/trivial/lower than MC] compared to the 
MC group (Figure 2).  
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Peak stroke volume 
There was no significant between-group differences in SVpeak at any time point [baseline; t(37)=-
0.004; p=0.997, post-training; t(38)=-1.176; p=0.247, or follow-up; t(31)=-1.576; p=0.125]. 
Following training, SVpeak increased in the MC group [t(15)=-3.794; p=0.002], and remained 
elevated from pre-training at follow-up [t(11)=-2.643; p=0.023]; but did not change in the OC 
group [post-training; t(22)=-1.694; p=0.104, follow-up t(19)=-0.583; p=0.566]. There was no 
significant group x time interaction for the OC group compared to the MC group following 
training [F(1,37)=1.055, p=0.311]; data are presented in Table 3. Standardised between-group 
differences for within-                    ’  D                                       
possibly lower SVpeak adaptation to training [-0.28±0.48 (-0.76- 0.20); 3/34/63% 
higher/trivial/lower than MC] compared to the MC group (Figure 2).  
 
Respiratory quotient  
    M                                                                     [baseline; t(39)=-
2.151; p=0.038, post-training; t(39)=-2.533; p=0.015, follow-up; t(33)=-2.342; p=0.025]. 
Following training, R   increased in the OC [t(24)=-2.273; p=0.032] but not the MC [t(15)=-
1.831; p=0.087) group, and returned to pre-training values at follow-up [OC; t(21)=-0.405; p=-
.690, MC; t(12)=-0.158; p=0.877]                                                            
[F(1.972, 59.146)=0.129, p=0.877]; data are presented in Table 3. Standardised between-group 
differences for within-                    ’  D                    OC use compared to normal 
menstrual                                               adaptation to training [0.02±0.52 (-0.50-
0.54); 24/56/20% higher/trivial/lower than MC] (Figure 2).  
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Minute ventilation  
                                -                           2slope at each time point [baseline; 
t(39)=-1.128; p=0.266, post-training; t(39)=1.741; p=0.090, follow-up; t(33)=0.552; p=0.585]. 
There were no changes in        2slope following training [OC; t(24)=-0.460; p=0.650, MC; 
t(15)=0.249; p=0.807] or at follow-up [OC; t(21)=-0.855; p=0.402, MC; t(12)=-1.2780; 
p=0.225].                                                              2slope [F(1.551, 
46.539)=1.132, p=0.319]; data are presented in Table 3.                     -                  
          -                    ’  D                                                        
                                                 2slope adaptation to training [0.09±0.45 (-0.36-
0.54); 31/59/10% higher/trivial/lower than MC] (Figure 2). 
 
Peak heart rate and rating of perceived exertion  
There was no significant difference between MC and OC group for HRpeak or RPEpeak at each of 
the three time points (all p>0.05). There were no differences in HRpeak or RPEpeak pre-, post- or 
de-training in the OC and MC-groups (all p>0.05). There was no significant group x time 
interaction for HRpeak [F(1.738, 71.258)=0.089, p=0.891] or RPEpeak [F(1.970, 80.780)=1.981, 
p=0.145].  
 
Discussion  
The present study assessed the influence of OC                                           2peak, 
PPO,   peak, SVpeak     , HRpeak, RPEpeak             2slope) to four weeks of SIT in 
recreationally-active women under stringently-controlled ovarian hormone conditions. 
Additionally, the maintenance of these adaptations during a four-week follow-up period after 
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SIT was assessed. This study found that OC                                                
   2peak       peak adaptations to SIT in recreationally-active women, but did not influence PPO 
or other adaptations. Interestingly, OC use appeared to protect against the loss of peak 
physiological and performance adaptations during the four-week follow-up period. This is the 
first study to investigate the influence of OC use on peak exercise adaptations to training.  
 
                                   2peak in the OC (8.5%), MC (13.0%), and LPD (13.6%) 
groups in the present study are similar to those previously reported in recreationally-active 
women for whom hormone levels were not established. Indeed, several SIT studies in 
recreationally-active women have found that two to eight weeks of SIT comprising four to 10 
bouts of 30 seconds to four minutes in duration (variable intensity) with one to four minutes’      
                             0 05                    5-   0        2max (1, 14, 15, 31, 39, 41). 
Of these, only one study (41), excluding OC users, attempted to control for menstrual cycle 
phase by testing in the follicular phase (determined by onset of menstruation), yet did not verify 
menstrual cycle phase using hormone measures. With up to 57% of reproductive-aged women in 
worldwide reporting OC use (16), it is likely that the majority of participants within these studies 
were taking an OC. Therefore, the findings of the present study suggest that the    2peak 
adaptation reported within these previous studies, where no consideration of OC use or ovarian 
hormone concentrations in the methodology is apparent, were likely influenced by OC use. 
However, it must be noted that there is a wide array of hormone contraceptives in use. As this 
study specifically investigation low-dose combined OCs, with 20-30 μg ethinyl estradiol and a 
second or third generation progestin, this conclusion cannot yet be drawn for higher dose 
formulations and OCs that use earlier or later generation progestins. Furthermore, while not 
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statistically significant, it is important to note that, on average, the OC group lost weight over the 
duration of the study, while the MC group and LPD sub-group gained a small amount of weight. 
When variables of interest were adjusted for body mass and lean body mass, the interactions 
remained true. Therefore, it is unlikely that these small, non-significant changes in body mass 
influenced the outcomes of the study. The significant improvement demonstrated by the LPD 
sub-group, de                                                                          2peak 
adaptation in the OC group is an actual finding and not an artefact of the small non-significant 
differences in body mass between groups. 
 
Normative data developed for women mu                                                    
                   2peak as a marker of cardiorespiratory fitness and/or health may need to 
consider OC use or ovarian hormone status during interpretation. Furthermore, OC status should 
be considered by coaches and sports scientist when interpreting physiological responses to 
training blocks, and the utilisation of measures and standards that are not influenced by ovarian 
hormone status should be a priority within female-specific populations.  
 
In the one study reporting                         2peak during a follow-up period, Ready and 
colleagues (31) observed that only 24% of the improvements       2peak following training were 
maintained after a two-week follow-up. However, the authors did not consider/report OC use or 
menstrual status. Results of the present study suggest that                        O2peak 
adaptation following a training intervention, it may also minimise the loss of the training effect 
for the parameter.    2peak returned towards baseline after follow-up in both groups; however, 
                   3        2peak adaptations to training, compared to naturally-menstruating 
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women,                            2peak adaptation to training. It is important to note that while 
the OC                             2peak adaptations to training, and therefore may have been 
expected to exhibit lower decline towards baseline, both                               
                   2peak at follow-up (both approximately 4.4%). Therefore, OC use may alter 
the time course of training adaptations, and the use of OC during lower training periods, tapering 
or injury, may indeed be a useful practise to minimise the negative effects of detraining. 
Inclusion of longer training and follow-up periods with intermediate testing would shed further 
light on this phenomenon.  
 
Furthermore, it must also be noted that participants in the present study were already physically 
active, and were encouraged to maintain their habitual levels of physical activity throughout 
training and follow-up, and merely refrain from performing SIT during the follow-up phase. 
Therefore, results from the present study may not be comparable to studies where habitual 
exercise was completely ceased. Furthermore, while not statistically significant, there was an 
average of 18 min/week difference in physical activity levels between the OC and MC groups at 
follow-up. Additionally, the LPD group reported                                              
                                                              M                 -          
                                          2peak following detraining (MC; +7.9% and LPD; 
+8.4%, compared with OC; +3.6%). Whilst this non-significant between-group difference in 
physical activity levels is likely negligible on a day to day basis, it may have contributed to the 
different responses observed in the loss of peak exercise after follow-up between groups. 
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There i                                                                                            
                                                                                    2peak 
adaptation (2). Longitudinal studies have demonstrated that training-induced                 2peak 
                                                                                           
       -                                             2peak training adaption is predominantly 
related to central adaptions rather than peripheral adaptation (2). Following SIT, there was a 
significant increase in   peak of +4.0% and +16.1% in the OC group and the MC group, 
respectively, with the MC group showing a significantly greater improvement (p=0.013). A  
      -      peak returned towards pre-training levels in both groups, and there were no between-
group differences at follow-up. When considered in conjunction with the significant positive 
relationship                      2peak and change in   peak with training (r=0.362, p=0.020), 
this, at least in part,                          2peak response to training observed in OC users 
compared to naturally-menstruating women.  
 
Reductions in blood volume and cardiac output have previously been found following de-
training in men and women (13, 26)                                                            
   2peak during follow-up.                                                               
                       2peak with training. The effects of oestrogen and progesterone on plasma 
volume expansion and fluid retention [through the potential mechanisms of capillary 
filtration/permeability and stimulation of nitric oxide production and subsequent effect on the 
renin-angiotensin aldosterone system (9)] may explain why the OC group showed a practically 
meaningful (though not statistically significant) lower decline      peak (due to potential 
preservation of training-induced blood volume changes) four weeks following the completion of 
AC
CE
PT
ED
Copyright © 2016 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
SIT training (4.0% in the OC group vs. 7.7% in the MC group) (35).                  
                                                                                               
                                        2peak with training, therefore further research should 
investigate peripheral adaptations, such as peripheral muscle deoxygenation or mitochondrial 
oxidative capacity, which may be associated with the discrepancy in physiological adaptations to 
exercise training between naturally-menstruating women and OC users.  
 
It is a further in                                                                              
                                                       peak adaptations to training in a 
similar manner to the OC group (both compared to the group with normal menstrual function). 
This result (see Table, Supplemental Digital Content, Luteal phase deficient participant 
demographics, control parameters, body composition, serum hormone concentrations and peak 
exercise parameters at baseline, following training and after a four-week follow-up period, 
http://links.lww.com/MSS/A819) provides preliminary evidence that luteal phase deficiency 
significantly influences cardiovascular adaptations to training. This suggests that circulating 
endogenous ovarian hormone concentrations may be more influential on adaptation to training 
compared to exogenous ovarian hormones. Indeed, previous research has demonstrated that high 
oestrogen and progesterone levels are independently associated with plasma volume expansion 
(37), in comparison to primarily circulating exogenous hormones (35). In contrast to previous 
speculation that the cardiovascular limitation to exercise training adaptation in OC users is 
primarily due to the influence of exogenous oestradiol on the cardiovascular system, this finding 
suggests that it may instead be the low endogenous oestradiol concentrations that are implicated.  
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Both OC and MC groups improved PPO by 13.1% and 13.8%, respectively, with no difference 
between groups. After a four-week follow-up period, PPO returned towards baseline, with just 
over half of the PPO adaptation preserved in both groups. As PPO is strongly correlated with 
exercise performance (17), the present data suggest performance adaptations to SIT, and the 
preservation of these adaptations following SIT, are not influenced by OC use. Therefore, 
depending on the aims of an intervention, it may be more appropriate to use non-physiological 
measures of performance, such as PPO, when assessing adaptation to training in women who 
have varied hormone status, due to the apparent impact of OC use on physiological parameters 
following a training intervention. However, further research investigating performance in 
competitive athletic women using sport-specific contexts and/or time-trials is needed to confirm 
this. There were no significant changes in peak HR                E  O2slope follow training, and 
no differences between groups were observed. While there were no significant between-group 
differences in SV adaptations to training, the transient effect of both endogenous and exogenous 
progestogens on HR may have masked any potential changes in peak HR and SV following 
training.  
 
We recognise several limitations of the present study. It is a notable limitation of the present 
study that no non-exercising control group was included, therefore the changes seen with training 
must be interpreted with caution. All participants were taking a monophasic OC; however, there 
were variations in androgenic (n=5), anti-androgenic (n=5) and non-androgenic (n=15) 
formulations. While no differences in training adaptations were present among the different OC 
formulations, the small sample size following sub-grouping may have limited our ability to 
detect differences; further investigation is necessary to confirm whether OC androgenicity 
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influences adaptation to training in women. Secondly, following training, the oestrogen and 
progesterone concentrations of women with normal menstrual function were significantly lower. 
Despite the challenges it posed, we chose to test within the mid-luteal phase within this study to 
ensure that endogenous ovarian hormones were as high as possible and compare to OC use when 
exogenous hormones were as high as possible and endogenous hormones were as low as possible 
to maximise the effect of ovarian hormones on outcome measures. While we are confident that 
the timing of testing, based on individual participant cycle lengths, was appropriate, it is possible 
that the sudden perturbation in energy balance caused by the sprint interval training program 
induced probably luteal phase deficiency within subsequent cycles in some women which is an 
important consideration for future training studies in women. Therefore, to minimise the 
influence of fluctuating ovarian hormones on study outcomes, it may be more practical to test in 
the early follicular phase during training interventions that could elicit luteal phase deficiency in 
at risk women.  
 
Thirdly, although self-report physical activity during the four-week period following completion 
of SIT training was not different between groups, objective monitoring would have minimised 
any potential recall bias associated with self-report measures. Finally, following serum hormone 
analyses, six naturally-menstruating women who completed the training intervention were 
excluded from the primary analysis as they did not meet the minimum progesterone 
concentration criterion for normal mid-luteal menstrual phase. Therefore, we recommend 
oversampling by 30% in normally-menstruating participants in studies including women, to 
account for the required exclusion of potential luteal-phase deficient participants from analysis. 
We have presented supplementary data which suggests that luteal-phase deficiency may indeed 
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influence cardiovascular adaptation to training. Whether forms of menstrual dysfunction 
influence adaptation to training is an important consideration in the area of female athletic 
performance and adaptation to training in physically-active women, and requires further 
investigation. 
 
In conclusion, this study suggests that compared to natural menstruation, OC use         
   2peak       peak adaptation to SIT in recreationally-active women, yet better preserves these 
adaptations following completion of SIT                               2peak. In contrast, PPO 
adaptation appeared unaffected by OC use. These findings demonstrate the clear need to consider 
exogenous hormone use in exercise training studies involving women of reproductive age. 
Further investigation is required to elucidate the influences of OC use compared to natural 
menstruation on the central and peripheral adaptations to exercise training, and how these may 
manifest in exercise performance.  
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Figure 1: Participant flow diagram  
 
Figure 2: Standardised between-group differences for within-group changes for the oral 
contraceptive group versus the menstrual cycle groups following training.  
   2peak: peak aerobic capacity; PPO: peak power output;   peak: peak cardiac output; HRpeak: 
peak heart rate; RPEpeak: peak rating of perceived exertion; SVpeak: peak stroke volume; RQpeak: 
peak respiratory quotient;       2slope: minute ventilation; min: minute; bpm: beats per minute.  
 
Supplemental Digital Content 
 
Supplementary Table 1: Luteal phase deficient participant demographics, control parameters, 
body composition, serum hormone concentrations and peak exercise parameters at baseline, 
following training and after a four-week follow-up period (n=6).  
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Table 1: Participant demographics, control parameters, body composition and serum hormone concentrations at baseline, following 
training and after a four-week follow-up period.  
 Oral contraceptive group (n=25) Menstrual cycle group (n=16) 
 Pre-training Post-training De-training Pre-training Post-training De-training 
Participant demographics and control measures   
Age  25.5±5.4  
(23.1-27.8) 
x x 27.6±5.4  
(24.5-30.8) 
x x 
Menstrual cycle length (days)  28±0  
(28-28) 
x x 30±2  
(29-31) 
x x 
Testing day (days)  17±4  
(16-19) 
18±6  
(16-21) 
19±5 
(16-21) 
23[20-24]  
(21-23)
#
 
23±4 
(21-26) 
23±2 
(21-24) 
Physical activity (min.wk
-1
) 247±64  
(222-272) 
235±61  
(211-258) 
246±64  
(221-271) 
229±44  
(210-247) 
217±43  
(199-234) 
228±43 
(210-246) 
Energy intake (kJ.kg
-1
.day
-1
) 8461± 3194 
(6896-10026) 
8490±2452  
(7103-9877) 
8385±2110 
(7077-9692) 
8373±2360 
(7179-9567) 
8490±1971 
(7269-9712) 
8267±2102 
(7078-9692) 
Body composition       
Body mass (kg) 63.6±7.8  
(60.3-66.8) 
63.4±7.2  
(60.4-66.3) 
62.5±7.1  
(59.4-65.6) 
66.1±8.7  
(61.0-71.1) 
66.4±8.7 
 (61.3-71.4) 
66.6±8.5 
 (61.7-71.4) 
Body mass index (kg.m
-2
) 22.6±2.1  22.6±2.1 22.6±2.1 23.0±2.1  23.0±2.1  23.0±2.1  
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(21.7-23.4)  (21.7-23.4)  (21.7-23.4) (21.8-24.2) (21.8-24.2) (21.8-24.2) 
Fat mass (kg) 20.7±4.8  
(18.7-22.7) 
20.5±4.6  
(18.6-22.4) 
20.1±2.0  
(18.2-22.0) 
22.7±4.7  
(20.0-25.4) 
22.6±5.0  
(19.8-25.5) 
22.7±4.7  
(20.0-25.4) 
Lean body mass (kg) 40.6±4.4  
(38.8-42.5) 
40.6±4.1  
(38.9-42.3) 
40.2±4.3  
(38.3-42.1) 
41.1±5.7  
(37.8-44.4) 
41.4±5.5  
(38.2-44.6) 
41.6±5.6  
(38.3-44.8) 
Lean body mass – legs (kg) 13.6±1.8  
(12.9-14.4) 
13.8±1.9  
(13.0-14.5) 
13.5±1.8  
(12.7-14.3) 
13.8±2.5  
(12.4-15.3) 
14.0±2.5  
(12.5-15.4) 
14.1±2.6  
(12.6-15.6) 
Body fat (%) 32.3±4.8  
(30.3-34.3) 
32.1±4.8  
(30.1-34.0) 
32.0±4.6  
(30.0-34.0) 
34.2±4.8  
(31.5-37.0) 
33.9±5.0 
 (31.0-36.8) 
34.0±5.0  
(31.1-36.9) 
Hormone and blood measures       
Oestradiol (pg.mL
-1
) 5.6 [5.0-10.3]  
(5.7-13.5) 
5.1[5.0-10.2]  
(-11.0-63.8) 
9.2[5.0-11.8]  
(6.7-16.2) 
136.4±61.9  
(102.1-170.7) 
107.8±73.1  
(67.3-148.3) 
68.8[40.8-123.6]  
(47.4-121.7) 
Progestogen (ng.mL
-1
) 0.6±0.3  
(0.4-0.7) 
0.5±0.3  
(0.4-0.6) 
0.5±0.3  
(0.4-0.7) 
13.1±6.6  
(9.4-16.8) 
1.1[0.8-5.9]  
(-0.1-9.6) 
1.0[0.6-4.0]  
(0.5-6.1) 
Total testosterone (ng.mL
-1
) 0.20±0.10  
(0.10-0.20) 
0.13±0.07  
(0.10-0.16) 
0.13±0.06  
(0.10-0.15) 
0.21±0.16  
(0.12-0.30) 
0.26±0.16  
(0.17-0.35) 
0.23±0.16  
(0.13-0.32) 
Sex-hormone-binding globulin 
(pg.mL
-1
) 
209.0±87.1  
(170.3-247.6) 
189.6±99.3  
(145.6-233.7) 
198.3±96.5  
(155.6-241.1) 
67.5±31.4  
(50.0-84.9) 
58.5[34.3-78.7]  
(45.4-74.9) 
71.0±49.3  
(42.5-99.4) 
Free androgen index (%) 7.8[4.2-8.5]  8.6±5.6  3.1[6.5-12.7]  25.6[13.8-42.0]  59.1±53.6  30.2[13.7-76.5]  
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(6.9-14.7) (6.1-11.0) (5.4-12.4) (12.8-82.6) (29.5-88.8) (20.6-77.1) 
Parametric data are presented as mean±SD (95% CI); non-parametric data are presented as median [IQR] (95% CI). *p<0.001 vs. oral contraceptive group; #p<0.01 vs. pre-
training 
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Table 2: Summary of attendance, adherence, heart rate, power output and rating of 
perceived exertion responses for each interval over 12 sessions (120 intervals) of 
training. 
 Oral contraceptive 
group (n=25) 
Menstrual cycle 
group (n=16) 
p-value 
Adherence (no. of intervals at target power) 95±21 (86-104) 89±23 (77-102) 0.311 
Adherence (% intervals at target power) 79±17 (72-86) 74±19 (64-85) 0.311 
Mean heart rate (bpm) 179±8 (176-182) 178±6 (175-181) 0.591 
Heart rate/peak heart rate (%) 98±3 (97-100) 97±3 (95-98) 0.329 
Mean power output (Watts)  229±37 (213-245) 233±48 (207-260) 0.871 
Power output/peak power output (%) 108±4 (107-110) 106±5 (103-108) 0.084 
Mean rating of perceived exertion (Borg 6-20) 17±2 (16-18) 17±1 (16-17) 0.915 
Data are presented as mean±SD (95%CI); independent t-test.  
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Table 3: Peak exercise parameters at baseline, following four weeks of training and after a four-week follow-up period. 
 Oral contraceptive group (n=25) Menstrual cycle group (n=16) 
 Baseline Post-training Follow-up Baseline Post-training Follow-up 
   2peak (L∙min
-1
) 2.3±0.4  
(2.1-2.5) 
2.5±0.4  
(2.3-2.6)* 
2.4±0.4  
(2.3-2.6)* 
2.3±0.5  
(2.1-2.6) 
2.6±0.5  
(2.4-2.9)* 
2.4±0.4  
(2.1-2.7)* 
PPO (Watts) 214.0±33.7 
(200.2-228.0) 
242.0±33.2  
(228.3-255.7)* 
230.2±33.6  
(215.7-244.7)*
+
 
215.6±44.1 
 (192.1-239.1) 
245.3±40.6 
 (223.6-266.9)* 
230.8±33.0  
(211.7-249.8)*
#
 
  peak (L∙min
-1
) 19.6±3.3  
(18.2-21.0) 
20.4[19.1-22.4]  
(19.9-22.2)
#
 
19.8±2.7  
(18.7-21.0) 
19.2±3.1  
(17.5-20.8) 
22.3±2.1 
 (21.2-23.4)* 
20.2±2.9  
(18.5-21.9)
#
 
HRpeak (bpm) 182.0±9.0  
(178.1-185.9) 
184.8±8.5  
(181.3-188.3)
#
 
183.3±9.5  
(179.7-187.9) 
182.3±7.1 
 (178.5-186.0) 
184.8±6.2 
(181.5-188.0) 
183.6±7.0 
 (179.6-187.7) 
RPEpeak (Borg) 19.0[17.0-20.0]  
(17.9-19.0) 
18.0[17.0-19.0]  
(17.6-18.7) 
18.0[17.0-19.0] 
(17.7-18.9) 
18.0[17.0-19.0]  
(17.3-18.4) 
18.3±1.3 
 (17.6-18.9) 
17.9±1.4 
 (17.1-18.6) 
SVpeak (mL) 103.2±20.7  
(94.3-112.2) 
109.5±15.9  
(102.8-116.2) 
102.0±15.5  
(95.0-109.1) 
103.3±19.1  
(93.1-113.4) 
115.0±11.8* 
(108.7-121.2) 
112.0±20.7*  
(98.9-125.1) 
   peak 1.26±0.06  1.29±0.05*  1.27±0.05  1.31±0.07  1.33±0.05  1.32±0.05  AC
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(1.24-1.29) (1.27-1.31) (1.25-1.29) (1.27-1.34) (1.30-1.36) (1.28-1.35) 
      2slope 31.4±4.5  
(31.7-4.3) 
31.7±4.3  
(29.9-33.5) 
31.6±4.2  
(29.8-33.5) 
29.7±4.6  
(27.3-32.2) 
29.6±2.8  
(28.1-31.0) 
30.9±3.4
+
  
(28.8-32.9) 
   2peak: peak aerobic capacity; PPO: peak power output;   peak: peak cardiac output; HRpeak: peak heart rate; RPEpeak: peak rating of perceived exertion; SVpeak: peak 
stroke volume; RQpeak: peak respiratory quotient;        2slope: minute ventilation; min: minute; bpm: beats per minute. Parametric data are presented as mean±SD 
(95%CI); non-parametric data are presented as median [IQR] (95%CI). *p<0.01 vs. pre; #p<0.05 vs. pre; +p<0.01 vs. post. 
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Supplementary Table 1: Luteal phase deficient participant demographics, control parameters, 
body composition, serum hormone concentrations and peak exercise parameters at baseline, 
following training and after a four-week follow-up period (n=6).  
 
 Pre-training Post-training De-training 
Participant demographics and control measures 
Age  
(years) 
23.0±3.0  
(20.1-25.4)* 
x x 
Menstrual cycle 
length (days)  
34±5  
(31-38)*^ 
x x 
Testing day  
(days)  
22±3  
(19-24)
#
 
24±3  
(21-27) 
23±2  
(21-25) 
Physical activity  
(min.wk
-1
) 
252±89 
(215-289) 
235±72 
(205-265) 
233±92 
(195-272) 
Energy intake  
(kJ.kg
-1
.day
-1
) 
7924±1911 
(6394-9455) 
7972±2046 
(6334-9609) 
7954±1285 
(6926-8982) 
Body composition     
Body mass  
(kg) 
58.0±7.8*  
(49.9-66.2) 
58.6±7.4*  
(50.8-66.3) 
58.8±7.7*  
(50.7-66.9) 
Body mass index  
(kg.m
-2
) 
21.5±2.2  
(19.2-23.8) 
21.5±2.2  
(19.2-23.8) 
21.5±2.2  
(19.2-23.8) 
Fat mass  
(kg) 
16.7±4.7* 
(11.8-21.6) 
16.4±5.2  
(10.9-21.9) 
16.7±5.3  
(11.2-22.3) 
Lean body mass  
(kg) 
39.0±4.6  39.8±4.6  39.8±4.3  
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(34.2-43.9) (35.0-44.6) (35.2-44.3) 
Lean body mass - 
legs (kg) 
12.8±1.8  
(10.9-14.6) 
13.0±1.7  
(11.2-14.8) 
13.0±2.0  
(10.9-15.2) 
Body fat  
(%) 
28.5±5.4* 
(22.8-34.2) 
27.8±6.4*  
(21.1-34.5) 
28.1±5.9*  
(21.9-34.3) 
Hormone and blood measures 
Oestradiol  
(pg.mL
-1
) 
88.5±78.2  
(-8.5-185.6) 
56.6±32.3  
(22.7-90.4) 
68.9±58.9  
(7.1-130.7) 
Progestogen  
(ng.mL
-1
) 
0.8±0.2*  
(0.5-1.0) 
0.8±0.2  
(0.6-1.0) 
0.8±0.3  
(0.5-1.2) 
Total testosterone   
(ng.mL
-1
) 
0.37±0.27  
(0.04-0.70) 
0.37±0.23  
(0.13-0.60) 
0.31±0.17  
(0.13-0.49) 
Sex-hormone-
binding globulin 
(pg.mL
-1
) 
71.6±58.2^  
(-0.6-143.9) 
67.5±46.3^  
(18.9-116.1) 
67.0±47.9^  
(16.7-117.3) 
Free androgen 
index (%) 
57.5[32.2-145.1]*  
(-54.9-256.0) 
99.3±121.3*  
(-28.0-226.6) 
50.2[34.6-115.0]*  
(-13.7-172.0) 
Peak exercise parameters  
   2peak  
(L∙min-1) 
2.2±0.5 
 (1.6-2.7) 
2.5±0.5  
(1.9-3.1)*  
2.3±0.5 
 (1.8-2.8) 
PPO  
(W) 
208.3±45.7  
(160.3-256.3) 
233.3±43.1 
 (188.1-278.5)* 
222.9±42.9 
(177.9-267.9) 
  peak  
(L∙min-1) 
17.6±4.0 
 (13.4-21.8) 
18.7±3.0  
(15.6-21.9)^ 
18.4±2.4  
(15.8-20.9) 
HRpeak  
(bpm) 
177.7±5.4  
(172.0-183.4) 
179.8±5.3 
(174.2-185.4) 
181.3±3.6 
(177.6-185.1) 
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RPEpeak  
(Borg) 
17.7±1.5  
(16.1-19.3) 
18.0±1.3 
 (16.7-19.3) 
17.5[16.0-18.0]  
(16.1-18.2) 
SVpeak  
(mL) 
92.8±18.8  
(73.0-112.5) 
92.2±14.2  
(77.3-107.1) 
91.4±16.6  
(70.8-112.0) 
   peak 1.30±0.07  
(1.23-1.38) 
1.33±0.07  
(1.25-1.40) 
1.36±0.12
# 
 
(1.21-1.51) 
       2slope 27.2±1.3  
(25.8-28.6) 
29.5±2.8
#
  
(29.6-29.9) 
28.8±3.0  
(25.1-32.5) 
 
   2peak: peak aerobic capacity; PPO: peak power output;   peak: peak cardiac output; HRpeak: peak 
heart rate; RPEpeak: peak rating of perceived exertion; SVpeak: peak stroke volume; RQpeak: peak 
respiratory quotient;        2slope: minute ventilation; min: minute; bpm: beats per minute. 
Parametric data are presented as mean±SD (95%CI); non-parametric data are presented as median 
[IQR] (95%CI). *p<0.05 vs. normal menstrual function group; ^p<0.05 vs. oral contraceptive group; 
#
p<0.01 vs. pre-training 
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